Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Levofloxacin was recently (May 2008) approved by the U.S. Food and Drug Administration as a treatment for children following inhalational exposure to anthrax. Given that no clinical trials to assess the efficacy of a chosen dose was conducted, the basis for the dose recommendation was based upon pharmacometric analyses. The objective of this paper is to describe the basis of the chosen pediatric dose recommended for the label. Pharmacokinetic (PK) data from 90 pediatric patients receiving 7 mg/kg of body weight levofloxacin and two studies of 47 healthy adults receiving 500 and 750 mg/kg levofloxacin were used for the pharmacometric analyses. Body weight was found to be a significant covariate for levofloxacin clearance and the volume of distribution. Consistently with developmental physiology, clearance also was found to be reduced in pediatric patients under 2 years of age due to immature renal function. Different dosing regimens were simulated to match adult exposure (area under the concentration-time curve from 0 to 24 h at steady state, maximum concentration of drug in serum at steady state, and minimum concentration of drug in serum at steady state) following the approved adult dose of 500 mg once a day. The recommended dose of 8 mg/kg twice a day was found to match the exposure of the dose approved for adults in a manner that permitted confidence that this dose in children would achieve efficacy comparable to that of adults.
Li
Fang
F
Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. fang.li@fda.hhs.gov
Nandy
Partha
P
Chien
Shuchean
S
Noel
Gary J
GJ
Tornoe
Christoffer W
CW
D000293:Adolescent; D000375:Aging / Q000378:metabolism; D000881:Anthrax / Q000382:microbiology / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D001835:Body Weight / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D019570:Inhalation Exposure; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013171:Spores, Bacterial; D013607:Tablets
D000900:Anti-Bacterial Agents; D013607:Tablets; D064704:Levofloxacin; D015242:Ofloxacin